NovaBridge's Strategic Licensing Move
Recently, NovaBridge, a prominent player in the global biotechnology landscape, made a significant step by assigning its exclusive license for VIS-101 to Evergreen Medicines. This collaboration aims to fast-track the development of VIS-101, a promising therapy targeting wet age-related macular degeneration (AMD) and other eye diseases, across key Asian markets.
About the Collaboration
By partnering with Everest Medicines, NovaBridge is strategically positioning itself to leverage Everest's extensive expertise in clinical development and commercialization in Greater China and other parts of Asia. This collaboration is expected to enhance the development process, bringing potential benefits of VIS-101 to patients sooner, thanks to the combined strengths of both companies.
Meet Ian Woo
A notable addition to NovaBridge's Board of Directors is Mr. Ian Woo, who has a proven track record in biopharma finance and operations. As the President and CFO of Everest Medicines, his insights and experience are set to propel NovaBridge towards achieving its ambitious goals in the biopharmaceutical sector.
Understanding VIS-101
VIS-101 is not just another therapy; it represents innovation in treating serious eye conditions. This bifunctional biologic targets both VEGF-A and ANG-2, presenting a compelling option for patients suffering from wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO). Its development is currently in advanced stages, with a Phase 2 study underway in China, paving the way for a Phase 3 readiness targeted for 2026.
The Science Behind VIS-101
Unlike traditional therapies, VIS-101 distinguishes itself by potentially offering more effective and durable treatment options. This could significantly improve outcomes for patients who have limited responses to existing treatments. The ongoing research indicates exciting possibilities for improved patient care.
NovaBridge's Vision for the Future
NovaBridge is committed to transforming the landscape of biopharmaceuticals by integrating scientific advancement with effective strategies. The company aims to bridge the gap between innovative discoveries and patient accessibility to cutting-edge therapies. By focusing on revolutionary treatments like VIS-101 and Givastomig, NovaBridge is dedicated to improving health outcomes globally.
The Broader Pipeline
In addition to VIS-101, NovaBridge is advancing several other therapeutics, including Givastomig, which targets Claudin 18.2 in the treatment of gastric cancer. This diverse pipeline underscores the company’s commitment to addressing critical healthcare needs across various disease areas.
Conclusion
The collaboration between NovaBridge and Everest Medicines represents an exciting advancement in the fight against serious eye diseases. With the dedicated efforts of both companies, VIS-101 stands out as a promising candidate that can potentially redefine treatment approaches in ophthalmology.
Frequently Asked Questions
What is VIS-101?
VIS-101 is a bifunctional biologic drug targeting VEGF-A and ANG-2, aimed at treating wet AMD, DME, and RVO.
Who is behind the development of VIS-101?
Visara, a subsidiary of NovaBridge, is responsible for the development and commercialization of VIS-101.
What are the expected benefits of partnering with Everest Medicines?
Everest Medicines brings extensive clinical and commercialization expertise, which can accelerate the development and accessibility of VIS-101 in key Asian markets.
When is VIS-101 expected to be ready for Phase 3 trials?
VIS-101 is anticipated to be ready for Phase 3 trials by 2026.
How does NovaBridge support innovative drug development?
NovaBridge combines its deep biological expertise with strategic operational frameworks to expedite the translation of research into impactful therapies.
